US 12,133,917 B2
Pediatric dosage forms, methods of making and using
Praful Balavant Deshpande, Waterford (IE); Stephen James Quinlan, Waterford (IE); Marta Golec, Waterford (IE); John Gerard O'Brien, Waterford (IE); James Joseph McDonald, Waterford (IE); Reem Elamein Elsiddig, Waterford (IE); and Ken O'Shea, Waterford (IE)
Assigned to EIRGEN PHARMA LTD., Waterford (IE)
Filed by EIRGEN PHARMA LTD., Waterford (IE)
Filed on Sep. 17, 2021, as Appl. No. 17/478,395.
Application 17/478,395 is a continuation of application No. 17/224,768, filed on Apr. 7, 2021.
Application 17/224,768 is a continuation of application No. 16/869,273, filed on May 7, 2020, granted, now 11,000,480.
Application 16/869,273 is a continuation of application No. PCT/IB2019/057360, filed on Aug. 30, 2019.
Claims priority of provisional application 62/725,940, filed on Aug. 31, 2018.
Prior Publication US 2022/0000783 A1, Jan. 6, 2022
Int. Cl. A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 31/592 (2006.01); A61K 31/593 (2006.01)
CPC A61K 9/1652 (2013.01) [A61K 9/0002 (2013.01); A61K 9/0053 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1694 (2013.01); A61K 31/592 (2013.01); A61K 31/593 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A tablet, consisting of:
a mixture of 25-hydroxyvitamin D3, microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, and silicon dioxide, or
a mixture of 25-hydroxyvitamin D, microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, silicon dioxide and a disintegrant,
wherein the 25-hydroxyvitamin D3 is the sole active agent in the tablet.